Diffuse Large B-cell Lymphoma (combination with rituximab-gemcitabine-dexamethasone-platinum (R-GDP)) | XPORT-DLBCL-030
Indication: DLBCL
Title: Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Drug: selinexor
Please visit clinicaltrials.gov for more information about this study.
Phase I | Phase II | Phase III |
---|---|---|
Phase I | Phase II | Phase III |